Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
TRICOR
Generic name / active ingredient
fenofibrate tablets
Dosage-form class
Fenofibrate oral tablets: 48 mg yellow unscored tablet imprinted FI and 145 mg white unscored tablet imprinted FO; two historical 90-tablet bottles
Route
Oral
Record reviewed
2026-08-30

Copy from the pack in hand

Source-linked reading points

  • 48 mg and 145 mg are labelled fenofibrate amounts per tablet. '90 Tablets' is the bottle count, not 90 tablets per dose, and 145 does not permit self-assembling three 48 mg tablets.
  • The 2025 label says swallow whole and not to crush, break, dissolve or chew. Both tablets are unscored. If swallowing is difficult or a strength change is considered, ask the pharmacist or prescriber to review another appropriate product.
  • The label bases geriatric dosage selection on kidney function. Age 65 or older, renal impairment, uncontrolled hypothyroidism, and use with a statin or colchicine require priority review of myopathy and rhabdomyolysis risk. Do not self-stop or self-add from the page.
  • Coumarin anticoagulants such as warfarin, immunosuppressants, potentially nephrotoxic medicines and bile-acid resins belong on the review list. Unexplained muscle pain/weakness with fever or malaise, dark urine, jaundice, swelling of the face/lips/tongue/throat or breathing trouble requires prompt medical contact; severe acute features require local emergency care.

Reviewed presentation examples — compare every field

  • Fenofibrate 48 mg per tablet; 90-tablet bottle; U.S. brand listing discontinuedNDC 0074-3173-90
  • Fenofibrate 145 mg per tablet; 90-tablet bottle; U.S. brand listing discontinuedNDC 0074-3189-90

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-30
Source record
4 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image